Glenn Merlino

Dr. Glenn Merlino


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Science
Verified
Journal Article
Closed access
CSChristine N. Spencer
Christine N. Spencer
JMJennifer L. McQuade
Jennifer L. McQuade
VGVancheswaran Gopalakrishnan
Vancheswaran Gopalakrishnan
JMJohn A. McCulloch
John A. McCulloch
MVMarie Vetizou
Marie Vetizou
JWJennifer A. Wargo
Jennifer A. Wargo
Another benefit of dietary fiber: The gut microbiome can modulate the immune system and influence the therapeutic response of cancer patients, yet the mechanisms underlying the effects of microbiota are presently unclear. Spencer et al . add to our understanding of how dietary habits affect microbiota and clinical outcomes to immunotherapy. In an observational study, the researchers found that melanoma patients reporting high fiber (prebiotic) consumption had a better response to checkpoint inhibitor immunotherapy compared with those patients reporting a low-fiber diet. The most marked benefit was observed for those patients reporting a combination of high fiber consumption and no use of over-the-counter probiotic supplements. These findings provide early insights as to how diet-related factors may influence the immune response. —PNK

1 September 2015 in Cell
Verified
Journal Article
Closed access
CDChi-Ping Day
Chi-Ping Day
GMGlenn Merlino
Glenn Merlino
TDTerry Van Dyke
Terry Van Dyke

21 January 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HTHisashi Takayama
Hisashi Takayama
WLWilliam J. LaRochelle
William J. LaRochelle
RSRichard Sharp
Richard Sharp
TOToshiyuki Otsuka
Toshiyuki Otsuka
PKPaul Kriebel
Paul Kriebel
GMGlenn Merlino
Glenn Merlino
Hepatocyte growth factor/scatter factor (HGF/SF) is a mesenchymally derived, multifunctional paracrine regulator possessing mitogenic, motogenic, and morphogenetic activities in cultured epithelial cells containing its tyrosine kinase receptor, Met. c- met has been implicated in oncogenesis through correlation of expression with malignant phenotype in specific cell lines and tumors. Paradoxically, however, HGF/SF can also inhibit the growth of some tumor cells. To elucidate the oncogenic role of HGF/SF in vivo , transgenic mice were created such that HGF/SF was inappropriately targeted to a variety of tissues. HGF/SF transgenic mice developed a remarkably broad array of histologically distinct tumors of both mesenchymal and epithelial origin. Many neoplasms arose from tissues exhibiting abnormal development, including the mammary gland, skeletal muscle, and melanocytes, suggesting a functional link between mechanisms regulating morphogenesis and those promoting tumorigenesis. Most neoplasms, especially melanomas, demonstrated overexpression of both the HGF/SF transgene and endogenous c- met , and had enhanced Met kinase activity, strongly suggesting that autocrine signaling broadly promotes tumorigenesis. Thus, subversion of normal mesenchymal–epithelial paracrine regulation through the forced misdirection of HGF/SF expression induces aberrant morphogenesis and subsequent malignant transformation of cells of diverse origin.

19 January 2011 in Nature
Verified
Journal Article
Open access
PDF file
MZM. Raza Zaidi
M. Raza Zaidi
SDSean Davis
Sean Davis
FNFrances P. Noonan
Frances P. Noonan
CGCari Graff-Cherry
Cari Graff-Cherry
THTeresa S. Hawley
Teresa S. Hawley
GMGlenn Merlino
Glenn Merlino
Exposure to ultraviolet (UV) radiation has been implicated in melanoma formation. Glenn Merlino and colleagues now show, in a mouse model, that UVB irradiation induces the recruitment of macrophages that produce interferon-γ to promote melanoma formation. The study suggests that agents that target interferon-γ may have therapeutic potential in patients with melanoma. Ultraviolet (UV) exposure has been implicated in melanoma formation. Here it is shown, in a mouse model, that UVB induces the recruitment of macrophages which produce interferon-γ to promote melanomagenesis. The study suggests that in melanomas, interferon-γ could be targeted therapeutically. Cutaneous malignant melanoma is a highly aggressive and frequently chemoresistant cancer, the incidence of which continues to rise. Epidemiological studies show that the major aetiological melanoma risk factor is ultraviolet (UV) solar radiation, with the highest risk associated with intermittent burning doses, especially during childhood1,2. We have experimentally validated these epidemiological findings using the hepatocyte growth factor/scatter factor transgenic mouse model, which develops lesions in stages highly reminiscent of human melanoma with respect to biological, genetic and aetiological criteria, but only when irradiated as neonatal pups with UVB, not UVA3,4. However, the mechanisms underlying UVB-initiated, neonatal-specific melanomagenesis remain largely unknown. Here we introduce a mouse model permitting fluorescence-aided melanocyte imaging and isolation following in vivo UV irradiation. We use expression profiling to show that activated neonatal skin melanocytes isolated following a melanomagenic UVB dose bear a distinct, persistent interferon response signature, including genes associated with immunoevasion. UVB-induced melanocyte activation, characterized by aberrant growth and migration, was abolished by antibody-mediated systemic blockade of interferon-γ (IFN-γ), but not type-I interferons. IFN-γ was produced by macrophages recruited to neonatal skin by UVB-induced ligands to the chemokine receptor Ccr2. Admixed recruited skin macrophages enhanced transplanted melanoma growth by inhibiting apoptosis; notably, IFN-γ blockade abolished macrophage-enhanced melanoma growth and survival. IFN-γ-producing macrophages were also identified in 70% of human melanomas examined. Our data reveal an unanticipated role for IFN-γ in promoting melanocytic cell survival/immunoevasion, identifying a novel candidate therapeutic target for a subset of melanoma patients.

1 May 2021 in Cancer Cell
Verified
Journal Article
Closed access
EPE. Elizabeth Patton
E. Elizabeth Patton
KMKristen L. Mueller
Kristen L. Mueller
DADavid J. Adams
David J. Adams
NANiroshana Anandasabapathy
Niroshana Anandasabapathy
AAAndrew E. Aplin
Andrew E. Aplin
GMGlenn Merlino
Glenn Merlino